Pathology News
admin

About admin@pathologynews.com

This author has not yet filled in any details.
So far admin@pathologynews.com has created 1089 blog entries.

August 2022

The Future of Artificial Intelligence in Digital Pathology

2022-08-03T09:07:09+00:00

During the last 5 years, academic and commercial actors have developed new technical solutions for a diverse set of tasks, including tissue segmentation, cell detection, mutation prediction, prognostication and prediction of treatment response. In the light of limited overall resources, it is presently unclear for researchers, practitioners and policymakers which of these topics are stable enough for clinical use in the near future and which topics are still experimental, but worth investing time and effort into.

The Future of Artificial Intelligence in Digital Pathology2022-08-03T09:07:09+00:00

Leica Biosystems Finalist for 2022 Victorian Manufacturing Hall of Fame Award

2022-08-02T11:36:37+00:00

MELBOURNE – Leica Biosystems is pleased to announce that the company was a finalist for the 2022 Victorian Manufacturing Hall of Fame Award for Manufacturer of the Year (Large Business). The Leica Biosystems facility in Melbourne was established in 2000, where more than 300 associates manufacture solutions to be shipped to laboratories around the world.

Leica Biosystems Finalist for 2022 Victorian Manufacturing Hall of Fame Award2022-08-02T11:36:37+00:00

July 2022

Rapid Deployment of Whole Slide Imaging for Primary Diagnosis in Surgical Pathology at Stanford Medicine: Responding to Challenges of the COVID-19 Pandemic

2025-11-24T10:21:39+00:00

Stanford Pathology began stepwise subspecialty implementation of whole slide imaging (WSI) in 2018 soon after the first US Food and Drug Administration approval. In 2020, during the COVID-19 pandemic, the Centers for Medicare & Medicaid Services waived the requirement for pathologists to perform diagnostic tests in Clinical Laboratory Improvement Amendments (CLIA)–licensed facilities. This encouraged rapid implementation of WSI across all surgical pathology subspecialties.

Rapid Deployment of Whole Slide Imaging for Primary Diagnosis in Surgical Pathology at Stanford Medicine: Responding to Challenges of the COVID-19 Pandemic2025-11-24T10:21:39+00:00

Digital Spatial Profiling Augments Pathology in Diagnosing Pulmonary Fibrosis

2022-07-27T09:23:44+00:00

A team of Canadian respiratory disease researchers reported that the p16 (cyclin-dependent kinase inhibitor) protein could be used to diagnose patients with the serious lung disease idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the most serious and common types of fibrotic interstitial lung diseases (ILDs), occurring most often in patients 60 years of age and older with an average survival time of three to five years. It is the number one reason for lung transplants. IPF is associated with increased expression of cyclin-dependent kinase inhibitors such as p16 and p21, and subsequent induction of cell cycle arrest, cellular senescence, and pro-fibrotic gene expression.

Digital Spatial Profiling Augments Pathology in Diagnosing Pulmonary Fibrosis2022-07-27T09:23:44+00:00

Deep Bio’s AI Support for Cancer Diagnosis has been Designated as an Innovative Product by the Korean Public Procurement Service

2022-07-26T13:21:56+00:00

Deep Bio: This designation marks the Korean government’s recognition of innovation for DeepDx®-Prostate ProSEOUL, SOUTH KOREA (PRWEB) JULY 25, 2022 Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software, announced that its AI solution for grading the severity of prostate cancer, DeepDx®-Prostate Pro, has been officially designated as an ‘Innovative Product (Fast Track II)’ by the Korean Public Procurement Service (PPS) in the bio-health sector, a public recognition of product excellence and innovation.‘Innovative Product Designation Program’ is a government program that aims to foster the development of innovative technologies and is operated by the Korean PPS, providing public access to breakthrough technologies. To select Innovative Products, a committee made up of the Korea PPS and experts in each field, such as bio-health, future automobiles, carbon neutrality, evaluate each registrant based on several criteria including public value and innovation. As a result, Deep Bio can now execute a purchase agreement with the PPS, and the product can be registered in the Public Procurement Market.With the registration of DeepDx®-Prostate Pro in the Public Procurement Market through this designation, the software as a medical device is now available to more than 300K national- and public institutions for purchase. With this opportunity, Deep Bio is expected to lay the groundwork for market expansion as well as demonstrate the clinical utility of its software.“We are delighted that the Korean PPS designated DeepDx®-Prostate Pro as an Innovative Product. It represents an official government recognition of the innovation of our state-of-the-art technology. Through this, potential clients at national- and public institutions can better access Deep Bio’s groundbreaking software for purchase”, said Sun-Woo Kim, CEO of Deep Bio. “We also hope that this will be a great opportunity to confirm the robust performance and value of our software when implemented into real clinical workflows,” added he.DeepDx®-Prostate Pro is a deep learning-based medical software that assists the histopathological diagnosis of prostate cancer by analyzing the Whole Slide Image (WSI) of the prostate needle biopsies. It automatically classifies the severity of prostate cancer based on the Gleason grading system, which is the most widely-used method for evaluating the degree of differentiation of prostate cancer tissues. The software has received Korea MFDS (Ministry of Food and Drug Safety) approval as a Class III medical device in November 2021. In a clinical validation study, the analysis by the software showed high concordance with the reference standard established by experienced board-certified pathologists. In addition, the software improved workflows by significantly reducing time spent by pathologists on analysis of each slide. The study results were published in Modern Pathology.Focusing not only on AI diagnostics but also on R&D, Deep Bio has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, as well as in various international conferences and events. The company also continues to build its global presence through overseas digital pathology solution providers in the US, Europe, and India, as well as conducting research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US.About Deep BioDeep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (> 700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit http://www.deepbio.co.kr.SOURCE: CISION PR Web

Deep Bio’s AI Support for Cancer Diagnosis has been Designated as an Innovative Product by the Korean Public Procurement Service2022-07-26T13:21:56+00:00

Non-Invasive Digital Diagnostic Test to Redefine Bladder Cancer Surveillance

2022-07-22T08:43:24+00:00

Cytobay, which focuses on developing a non-invasive methodology to diagnose cancer and monitor disease progression, will utilize Techcyte’s Clinical Pathology AI platform to analyze the cells and complete the diagnostic process.

Non-Invasive Digital Diagnostic Test to Redefine Bladder Cancer Surveillance2022-07-22T08:43:24+00:00

Jennifer Trueland Explores the Impact Investing in Digitising Diagnostics Will Have on Imaging

2022-07-20T14:16:30+00:00

Special Report: Imaging With investment being awarded to digitise diagnostics across the NHS in England, Jennifer Trueland explores what impact this will have on imaging. Last November, the Government announced investment of £24million to help digitise diagnostics across the NHS in England using the latest technology. Imaging was at the heart of it, with specific pledges on sharing scans across different settings, technology to improve the way that scans are requested, and moves to better enable them to be reported remotely. The investment was made in response to Professor Michael Richards’ review of NHS diagnostics capacity, which called for increased digitisation to drive efficiency and deliver seamless care. According to Dr Julian Elford, medical director of membership and business at the Royal College of Radiologists, and a consultant radiologist in Winchester, the investment was very welcome. “It could not be better timed,” he says. “This is the time for radiology. Radiology has been a Cinderella specialty for a while, but our era is here, which is great.” Patients across all medical specialities will require radiology at some point, he adds. “This is the time when we can encompass new technology and new methods of doing things, and digital is one of those,” Dr Elford explains. “The royal college welcomes that, and radiology is coming to the forefront, which is brilliant.” New money to tackle the challenges He hopes the new money will help tackle major challenges, not least workforce shortages. “Mike Richards recommended a massive increase in radiologists and radiographers, and we welcome that,” Dr Elford says. “But part of that [change] is going to be digital – we’ve got to change the way we do things and improve the way we do things to be more efficient.” IRefer, a clinical decision support tool to help other clinicians decide the best test or scan to request, is an example of this. “It saves doctor time, it saves the NHS money because we’re not doing the wrong test and wasting money, and more important than anything else, it’s what’s best for the patient,” Dr Elford says. “That’s a big deal.” This is already being rolled out and is working well, he says. He also welcomes funding for home reporting, that means that he as a radiologist does not have to go to the hospital to read scans. “In this country we have a massive backlog of scans that need reporting,” says Dr Elford. “Part of this money is being used to enable home reporting to the rolled out across the country – it’s more efficient for doctors and better for patients because the scans get reported more quickly.” Importance of networks The medical director of membership and business also welcomes funding for radiology networks – groups of trusts working together to share workforce and specialist expertise. This won’t solve problems of demand and a shortage of radiologists, but it helps. “It’s not actually extra capacity because it’s the same people doing it, but it smooths out the peaks and troughs,” Dr Elford says. According to Jane Rendall, UK managing director with Sectra, the new money was a catalyst, and is already making a difference, particularly in the development of radiology networks. “We had customers who had ambitions, but they just didn’t have the funding available,” she adds. “There was an urgency to spend it before the end of the NHS financial year, so the influx of funding really did help a lot of the networks.” It’s been a busy time, according to Rendall: “There’s been a lot of interest in people wanting to understand exactly what they could achieve with the funding that was available to them, so we had a lot of discussions – and I’m sure other suppliers did the same – trying to flex things to make sure they could get the most for the funding they had. “They also knew that if they could demonstrate progression on that network maturity matrix, if they were able to show a roadmap, it meant they would be able to get future funding as well.” Customers were particularly interested in bringing other “ologies” into their networks, Rendall also says, such as pathology, cardiology and ophthalmology, with the aim of achieving integrated diagnostics. “Basically an enriched level of imaging information in order to support diagnostic care,” she says. “For multi-disciplinary meetings, having all of your imaging, all of your pathology imaging, all of your reports, available on one system. The technology facilitates that enriched space.” As well as expanding the number of “ologies” they encompass, networks are also looking to share information more widely in geographical terms. Rendall for one would like to see this happen more, effectively creating a national “image sharing service” through networks, without going through a third party. “That’s super important because people are mobile, and are moving between imaging networks, so it’s good to facilitate that,” she adds. Working together For Ray Cahill, territory vice president at Change Healthcare, UK and Ireland, the pandemic has helped to make the case for working together across regions and nations. “The way they implemented imaging systems in the past, putting them in individual hospitals, did more harm than good,” he argues. “They created siloes of information, not in any way facilitating the journey of the patient who might go to multiple hospitals for one episode of illness. “What our customers are saying, what the government is mandating, and what we’ve seen happen in the last couple of years is that hospitals care coming together as consortiums.” Change is about people rather than technology, Cahill believes, reflecting on Ireland’s experience of bringing 50 hospitals together. “The technology takes a back step – it’s the process, and how we are going to suddenly operate in a way that we’ve never operated before,” he says. “People know – and Covid really shone a microscope on that – they have to join together, and they need clinical transformation supported by technology.” Gap in digital imaging Cahill also believes that the Department of Health and Care has recognised a gap in digital imaging and has allocated funding to modernise medical imaging and to facilitate clinical collaboration. But they also realise that technology has changed? “Imaging is at an inflection point. In the past, when we moved from film to digital, that was a massive change which produced significant productivity gains. But now it’s at the stage when it’s moving into cloud, and when imaging moves into the cloud, it changes the game altogether,” Cahill says. Cloud native – where something is built in the cloud situation – is probably going to be as revolutionary as film to digital, he adds. Again, Covid helped to make that point. “Accessibility is something that cloud native gives you,” Cahill says. “We anticipated that doctors were going to be mobile and that people weren’t going to be locked to their desks, and Covid has proven and accelerated that.” Still challenges ahead Even with well-functioning networks and the move to cloud, there are some challenges that remain, including workforce. That’s why some are looking to technologies such as AI – not to replace radiologists, but to help them work more efficiently. “With the amount of work that’s going to be needed to get through this backlog, and that’s not changing in the near term, radiologists will take all the help they can,” says Roberto Anello, managing director at Agfa. “AI’s got the ability to turbo-charge their workflow and turbo-charge their outputs.” He points to the Princess Alexandra NHS Trust’s experience in embedding Agfa Healthcare’s RUBEE for AI Framework, which allows consolidation of standards-based best-of-breed applications into specialty-based clinical packages. “We went live with Princess Alexandra with a couple of packages but specifically around lung nodule detection,” Anello explains. “They’re reporting a few things already. One is the time-saving for the radiologist – they’re now quoting up to 35% – because when they’re looking at a CT lung they can immediately see that there’s a nodule there that they might or might not have noticed, and it’s been sized for them. That accelerates their time.” Another advantage is that it’s an opportunity to look at something they might have missed, and consider whether it has an impact on their clinical decision-making, and it also helps to reduce clinical error. “That’s why we digitise clinical systems – to reduce that clinical error,” he says. “Combinations of all these things are resulting in tangible outcomes.” Exciting buzz Radiologists are excited about the potential of technologies like this, and are keen to get them into practice, Anello believes. “That was clear at a BIR [British Institute of Radiology] event I attended in London a few months back. That’s the buzz, everyone’s talking about it,” he adds. The challenge for the NHS is knowing what technologies to choose, but also to get over the “pilot” culture that means that lots of things are tested, but no decisions are taken. Anello thinks that AI is about to get to the point where it is being mainstreamed. “I think that will start to [change] a bit in the next 12-18 months because the technology will be more proven. We’re already starting to see that,” he adds. “I think there’s a real appetite within the NHS across all geographies to work in development partnership and collaboration, to really tease that out, test it, and really tailor those things.” Concluding, Anello believes it is “an exciting time for radiology”. “I don’t see any radiologist who doesn’t want to pursue it because they’re all looking for that extra edge, that extra assistance – anything that can accelerate the time they spend working on images and reporting, that can lead to a better outcome,” he says. Related PostsTREs in the NHS – how health data sharing is saving livesIndustry news in briefIndustry news in briefSupporting the greater use of data sharing across healthcare

Jennifer Trueland Explores the Impact Investing in Digitising Diagnostics Will Have on Imaging2022-07-20T14:16:30+00:00

How to get microscopes to where there are no microscopes? The X-wow project | Yuchun Ding

2025-05-06T13:42:03+00:00

Dr. Yuchun Ding, Co-Founder at X-WOW.com For pathologists and scientists microscope does not seem like a luxury, it is an everyday tool necessary to do their jobs. It is not a cheap tool, but there is no option not to have one, especially if you work in a pathology or microbiology lab. Otherwise, you cannot [...]

How to get microscopes to where there are no microscopes? The X-wow project | Yuchun Ding2025-05-06T13:42:03+00:00
Go to Top